ストックスクリーナーアプリを入手
47.37
0.55%
-0.26
Merus N V (MRUS) 最新ニュース
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (MRUS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks
La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab dans le carcinome épidermoïde de la tête et du cou positif PD-L1 positif en 1re ligne - GlobeNewswire Inc.
Merus Shares Are Up Today: What's Going On? - Benzinga
Merus Stock Surges on Breakthrough Therapy News - TipRanks
Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab -February 18, 2025 at 09:00 am EST - Marketscreener.com
Objective long/short (MRUS) Report - Stock Traders Daily
Petosemtamab granted Breakthrough Therapy designation by - GlobeNewswire
Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug - StockTitan
Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler - MarketBeat
Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials - MSN
Merus N.V.’s SWOT analysis: biotech firm’s stock poised for growth amid clinical trials - Investing.com Nigeria
BMO Capital Maintains Merus N.V. (MRUS) Outperform Recommendation - MSN
Guggenheim Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Receives Average Rating of “Buy” from Analysts - Defense World
Piper Sandler sets $84 target on Merus stock, cites drug potential - Investing.com Australia
FY2024 Earnings Forecast for Merus Issued By Leerink Partnrs - MarketBeat
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit -February 13, 2025 at 08:01 am EST - Marketscreener.com
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - The Manila Times
Revolutionary Cancer Treatment Updates: Merus CEO Takes Center Stage at Major Oncology Summit - StockTitan
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga India
Piper Sandler Initiates Merus at Overweight With $84 Price Target -February 13, 2025 at 07:36 am EST - Marketscreener.com
Piper Sandler sets $84 target on Merus stock, cites drug potential By Investing.com - Investing.com South Africa
Merus (NASDAQ:MRUS) Now Covered by Analysts at Wells Fargo & Company - MarketBeat
What is Leerink Partnrs’ Estimate for Merus FY2024 Earnings? - Defense World
Merus (NASDAQ:MRUS) Research Coverage Started at Wells Fargo & Company - Defense World
Q1 Earnings Estimate for Merus Issued By Leerink Partnrs - MarketBeat
Leerink Partnrs Comments on Merus’ Q1 Earnings (NASDAQ:MRUS) - Defense World
Wells Fargo sets $91 target on Merus stock, cites mCRC potential - MSN
Trend Tracker for (MRUS) - Stock Traders Daily
Wells Fargo sets $91 target on Merus stock, cites mCRC potential By Investing.com - Investing.com South Africa
Wells Fargo Initiates Merus at Overweight With $91 Price Target -February 07, 2025 at 08:40 am EST - Marketscreener.com
Merus Stock: Cancer Drug Study Results Spark Growth - sharewise
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewswire
Landmark Cancer Treatment: Merus's Bizengri Shows Promising Results for Untreatable Lung & Pancreatic Cancers - StockTitan
KBC Group NV Boosts Stake in Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
Analysts Set Merus (NASDAQ:MRUS) PT at $85.64 - MarketBeat
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff (NASDAQ:MRUS) - Seeking Alpha
Merus (NASDAQ:MRUS) Short Interest Down 15.5% in December - MarketBeat
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Will Merus' First Commercialized Drug, Bizengri, Drive Revenue Growth And Propel Stock Price? - RTTNews
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):